Foxy-5

DRACPC ID  DRACPC0037

Active Ingredients   Foxy-5

Description  A formylated, six amino acid, Wnt5a-derived peptide and wnt-5a mimetic with potential anti-metastatic activity. Upon intravenous administration, Wnt-5a mimic hexapeptide foxy-5 binds to and activates the wnt-5a receptors, Frizzled-2 and -5, which activates wnt-5a-mediated signaling. Increased wnt-5a signaling may inhibit endothelial tumor cell migration and invasion. This may decrease metastasis of susceptible tumor cells. However, foxy-5 does not affect tumor cell proliferation or apoptosis. Foxy-5 lacks a heparan sulfate-binding domain and contains a formyl group on its NH2-terminal methionine residue which decreases in vivo degradation. Decreased expression of wnt-5a protein is associated with increased motility of certain tumor cell types.

Synonyms  Wnt-5a Mimic Hexapeptide Foxy-5; Foxy-5

Type  Small Molecule

Disease  Prostate Cancer, Colorectal Cancer, Metastatic Colon Cancer, Metastatic Breast Cancer, Metastatic Prostate Cancer

Classification

  

Peptide and derivative

Structure Information


Molecular Formula  C26H42N6O12S2

Molecular Weight  694.8

Active Sequence  MDGCEL

Sequence Length  6

Modification  C-terminal HCO

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-2-[[(2S)-4-carboxy-2-[[(2R)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-formamido-4-methylsulfanylbutanoyl]amino]propanoyl]amino]acetyl]amino]-3-sulfanylpropanoyl]amino]butanoyl]amino]-4-methylpentanoic acid

InChI  InChI=1S/C26H42N6O12S2/c1-13(2)8-17(26(43)44)32-24(41)15(4-5-20(35)36)30-25(42)18(11-45)29-19(34)10-27-22(39)16(9-21(37)38)31-23(40)14(28-12-33)6-7-46-3/h12-18,45H,4-11H2,1-3H3,(H,27,39)(H,28,33)(H,29,34)(H,30,42)(H,31,40)(H,32,41)(H,35,36)(H,37,38)(H,43,44)/t14-,15-,16-,17-,18-/m0/s1

InChI_Key WFZPJYYCTSHDJI-ATIWLJMLSA-N

SMILES  CC(C)C[C@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC=O)CCSC)=O)CC(O)=O)=O)=O)CS)=O)CCC(O)=O)=O)C(O)=O

External Codes


PubChem CID  44628955

DrugBank Accession Number  DB13034

NCI Thesaurus Code  C113435  

UNII  CBZ9UL0ARB   GSRS

CAS  881188-51-8



Drug approval


Drug indication
    Foxy-5 has been used in trials studying the treatment of Prostate Cancer, Colorectal Cancer, Metastatic Colon Cancer, Metastatic Breast Cancer, and Metastatic Prostate Cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT02020291 Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients With Metastatic Breast, Colon or Prostate Cancer Metastatic Breast Cancer; Colorectal Cancer; Prostate Cancer Phase 1 Treatment
NCT02655952 Phase Ib Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacodynamic Response of Foxy-5 in Patients With Metastatic Breast-, Colon- or Prostate Cancer Metastatic Breast Cancer; Metastatic Colon Cancer; Metastatic Prostate Cancer Phase 1 Treatment
NCT03883802 A Randomized, Multicentre, Open-Label Controlled Phase II Trial of Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer Colon Cancer Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.